Skip to main content

Lyumjev News

Lyumjev (insulin lispro-aabc) Injection Approved by U.S. FDA for Children with Diabetes

October 14, 2022 – The U.S. Food and Drug Administration (FDA) approved an expansion of the indication for Eli Lilly and Company's rapid-acting mealtime insulin Lyumjev® (insulin lispro-aabc) ...

FDA Approves Lyumjev (insulin lispro-aabc injection) 100 units/mL for Use in Insulin Pumps

INDIANAPOLIS, Aug. 16, 2021 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved an expanded label for Eli Lilly and Company's (NYSE: LLY) rapid-acting insulin, Lyumjev (insulin...

FDA Approves Lyumjev (insulin lispro-aabc injection) for Type 1 and Type 2 Diabetes

INDIANAPOLIS, June 15, 2020 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Lyumjev (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), Eli Lilly and Company's...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Diabetes, Type 2, Diabetes, Type 1

Lyumjev patient information at Drugs.com